Research advances in tumor microenvironment and lymphoma treatment

doi:10.3760/cma.j.cn371439-20250225-00136

Abstract

Abstract:

The tumor microenvironment （TME） is a complex ecosystem comprising infiltrating cells and their secretory products， extracellular matrix components， and other non-cellular elements. The pathogenesis of lymphomas involves intricate interactions between neoplastic cells and the TME. While tumor morphology， immunophenotype， and molecular features remain well-established factors for prognostic prediction and therapeutic guidance， the role of non-tumor cell microenvironment components has gained increasing significance with advancing understanding of the biological mechanisms of lymphoma. Consequently， further exploration is warranted into lymphoma subtypes where TME plays a pivotal role in disease development， as well as novel therapeutic approaches and combination strategies targeting non-tumor cells and tumor-non-tumor cell interactions. Such efforts hold promise for providing unique insights into lymphoma management.

Key words: Lymphoma, Tumor microenvironment, Immune checkpoint inhibitors, Molecular targeted therapy

Liu Xiaoxuan, Guo Zhi. Research advances in tumor microenvironment and lymphoma treatment[J]. Journal of International Oncology, 2025, 52(12): 795-800.

References 51

[1]	Khurana A, Ansell SM. Role of microenvironment in non-Hodgkin lymphoma: understanding the composition and biology[J]. Cancer J, 2020, 26(3): 206-216. DOI: 10.1097/PPO.0000000000000446. pmid: 32496454
[2]	Wang L, Ding K, Zheng C, et al. Detachable nanoparticle-enhanced chemoimmunotherapy based on precise killing of tumor seeds and normalizing the growing soil strategy[J]. Nano Lett, 2020, 20(9): 6272-6280. DOI: 10.1021/acs.nanolett.0c01415. pmid: 32787161
[3]	Fowler NH, Cheah CY, Gascoyne RD, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies[J]. Haematologica, 2016, 101(5): 531-540. DOI: 10.3324/haematol.2015.139493. pmid: 27132279
[4]	Steidl C, Stevenson FK. Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas[J]. Blood, 2024, 143(12): 1057-1058. DOI: 10.1182/blood.2023021003.
[5]	Rudelius M, Rosenfeldt MT, Leich E, et al. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment[J]. Haematologica, 2018, 103(1): 116-125. DOI: 10.3324/haematol.2017.177162. pmid: 29079592
[6]	Ciavarella S, Vegliante MC, Fabbri M, et al. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue[J]. Ann Oncol, 2018, 29(12): 2363-2370. DOI: 10.1093/annonc/mdy450. pmid: 30307529
[7]	Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas[J]. N Engl J Med, 2008, 359(22): 2313-2323. DOI: 10.1056/NEJMoa0802885.
[8]	Riihijärvi S, Fiskvik I, Taskinen M, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a nordic phase Ⅱ trial[J]. Haematologica, 2015, 100(2): 238-245. DOI: 10.3324/haematol.2014.113472. pmid: 25381134
[9]	Xu-Monette ZY, Xiao M, Au Q, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL[J]. Cancer Immunol Res, 2019, 7(4): 644-657. DOI: 10.1158/2326-6066.CIR-18-0439. pmid: 30745366
[10]	Aoki T, Chong LC, Takata K, et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma[J]. Cancer Discov, 2020, 10(3): 406-421. DOI: 10.1158/2159-8290.CD-19-0680. pmid: 31857391
[11]	Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma[J]. Blood Adv, 2020, 4(7): 1367-1377. DOI: 10.1182/bloodadvances.2019001390. pmid: 32267932
[12]	Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase Ⅱ US intergroup study ECOG-ACRIN E1412[J]. J Clin Oncol, 2021, 39(12): 1329-1338. DOI: 10.1200/JCO.20.01375. pmid: 33555941
[13]	Younes A, Sehn LH, Johnson P, et al. Randomized phase Ⅲ trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(15): 1285-1295. DOI: 10.1200/JCO.18.02403. pmid: 30901302
[14]	Chen BJ, Dashnamoorthy R, Galera P, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma[J]. Oncotarget, 2019, 10(21): 2030-2040. DOI: 10.18632/oncotarget.26771. pmid: 31007846
[15]	Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering[J]. J Hematol Oncol, 2020, 13(1): 86. DOI: 10.1186/s13045-020-00910-5.
[16]	Lynn RC, Weber EW, Sotillo E, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance[J]. Nature, 2019, 576(7786): 293-300. DOI: 10.1038/s41586-019-1805-z.
[17]	Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma[J]. Blood, 2021, 137(19): 2621-2633. DOI: 10.1182/blood.2020007445.
[18]	Martín-Moreno AM, Roncador G, Maestre L, et al. CSF1R protein expression in reactive lymphoid tissues and lymphoma: its relevance in classical Hodgkin lymphoma[J]. PLoS One, 2015, 10(6): e0125203. DOI: 10.1371/journal.pone.0125203.
[19]	Hsi ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study[J]. Blood, 2019, 133(16): 1762-1765. DOI: 10. 1182/blood-2018-08-870915. pmid: 30723079
[20]	Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma[J]. Haematologica, 2012, 97(3): 410-415. DOI: 10.3324/haematol.2011.053199. pmid: 22058214
[21]	Jachimowicz RD, Pieper L, Reinke S, et al. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP[J]. Haematologica, 2021, 106(6): 1684-1692. DOI: 10.3324/haematol.2019.243287. pmid: 32381573
[22]	Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome[J]. J Clin Oncol, 2013, 31(2): 256-262. DOI: 10.1200/JCO.2011.39.9881. pmid: 23045593
[23]	Romano A, Parrinello NL, Vetro C, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy[J]. Br J Haematol, 2015, 168(5): 689-700. DOI: 10.1111/bjh.13198.
[24]	Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy[J]. Clin Cancer Res, 2012, 18(6): 1611-1618. DOI: 10.1158/1078-0432.CCR-11-1942. pmid: 22271878
[25]	Armand P, Engert A, Younes A, et al. Lumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase Ⅱ CheckMate 205 trial[J]. Clin Oncol, 2018, 36(14): 1428-1439. DOI: 10.1200/JCO.2018.79.3547.
[26]	Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial[J]. Lancet Oncol, 2016, 17(9): 1283-1294. DOI: 10.1016/S1470-2045(16)30167-X. pmid: 27451390
[27]	Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087[J]. Blood, 2019, 134(14): 1144-1153. DOI: 10.1182/blood.2019000324. pmid: 31409671
[28]	Bröckelmann PJ, Goergen H, Keller U, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial[J]. JAMA Oncol, 2020, 6(6): 872-880. DOI: 10.1001/jamaoncol.2020.0750. pmid: 32352505
[29]	Patel SS, Weirather JL, Lipschitz M, et al. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative[J]. Blood, 2019, 134(23): 2059-2069. DOI: 10.1182/blood.2019002206. pmid: 31697809
[30]	Tuscano JM, Maverakis E, Groshen S, et al. A phase Ⅰ study of the combination of rituximab and ipilimumab in patients with relapsed/refractory B-cell lymphoma[J]. Clin Cancer Res, 2019, 25(23): 7004-7013. DOI: 10.1158/1078-0432.CCR-19-0438. pmid: 31481504
[31]	Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma[J]. Blood, 2006, 108(9): 2957-2964. DOI: 10.1182/blood-2006-04-018218. pmid: 16825494
[32]	Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3⁺ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma[J]. Haematologica, 2008, 93(2): 193-200. DOI: 10.3324/haematol.11702.
[33]	Smeltzer JP, Jones JM, Ziesmer SC, et al. Pattern of CD14⁺ follicular dendritic cells and PD1⁺ T cells independently predicts time to transformation in follicular lymphoma[J]. Clin Cancer Res, 2014, 20(11): 2862-2872. DOI: 10.1158/1078-0432.CCR-13-2367. pmid: 24727328
[34]	Radtke AJ, Roschewski M. The follicular lymphoma tumor microenvironment at single-cell and spatial resolution[J]. Blood, 2024, 143(12): 1069-1079. DOI: 10.1182/blood.2023020999.
[35]	Küppers R, Stevenson FK. Critical influences on the pathogenesis of follicular lymphoma[J]. Blood, 2018, 131(21): 2297-2306. DOI: 10.1182/blood-2017-11-764365. pmid: 29666116
[36]	Herrera AF. Noncellular immune therapies for non-Hodgkin lymphoma[J]. Hematol Oncol Clin North Am, 2019, 33(4): 707-725. DOI: 10.1016/j.hoc.2019.03.007.
[37]	Blaker YN, Spetalen S, Brodtkorb M, et al. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era[J]. Br J Haematol, 2016, 175(1): 102-114. DOI: 10.1111/bjh.14201.
[38]	Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)[J]. Br J Haematol, 2014, 164(6): 811-821. DOI: 10.1111/bjh.12708.
[39]	Menter T, Tzankov A, Zucca E, et al. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy[J]. Br J Haematol, 2020, 189(4): 707-717. DOI: 10.1111/bjh.16414.
[40]	Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase Ⅲ study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2019, 37(14): 1188-1199. DOI: 10.1200/JCO.19.00010. pmid: 30897038
[41]	Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase Ⅱ DAWN study[J]. J Clin Oncol, 2018, 36(23): 2405-2412. DOI: 10.1200/JCO.2017.76.8853. pmid: 29851546
[42]	Amin R, Mourcin F, Uhel F, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma[J]. Blood, 2015, 126(16): 1911-1920. DOI: 10.1182/blood-2015-04-640912. pmid: 26272216
[43]	Serrat N, Guerrero-Hernández M, Matas-Céspedes A, et al. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax[J]. Blood Adv, 2020, 4(17): 4217-4231. DOI: 10.1182/bloodadvances.2020001584. pmid: 32898249
[44]	Balsas P, Palomero J, Eguileor Á, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma[J]. Blood, 2017, 130(4): 501-513. DOI: 10.1182/blood-2017-04-776740. pmid: 28533307
[45]	Navarro A, Beà S, Jares P, et al. Molecular pathogenesis of mantle cell lymphoma[J]. Hematol Oncol Clin North Am, 2020, 34(5): 795-807. DOI: 10.1016/j.hoc.2020.05.002.
[46]	Laurent C, Dietrich S, Tarte K. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm[J]. Blood, 2024, 143(12): 1080-1090. DOI: 10.1182/blood.2023021000.
[47]	Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton's tyrosine kinase[J]. Clin Cancer Res, 2020, 26(16): 4216-4224. DOI: 10.1158/1078-0432.CCR-19-3703. pmid: 32461234
[48]	Sugio T, Miyawaki K, Kato K, et al. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS[J]. Blood Adv, 2018, 2(17): 2242-2252. DOI: 10.1182/bloodadvances.2018018754. pmid: 30194138
[49]	Kim S, Kwon D, Koh J, et al. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified[J]. Virchows Arch, 2020, 477(1): 131-142. DOI: 10.1007/s00428-020-02790-z.
[50]	Phyo ZH, Shanbhag S, Rozati S. Update on biology of cutaneous T-cell lymphoma[J]. Front Oncol, 2020, 10: 765. DOI: 10.3389/fonc.2020.00765. pmid: 32477957
[51]	Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and sézary syndrome: a multicenter phase Ⅱ study[J]. J Clin Oncol, 2020, 38(1): 20-28. DOI: 10.1200/JCO.19.01056. pmid: 31532724